Cited by 659CAR-T cell therapy researchImmunotherapy and Immune ResponsesCRISPR and Genetic Engineering

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Open access

Ruella, Marco, Xu, Jun, Barrett, David M., Fraietta, Joseph A., Reich, Tyler J., Ambrose, David E., Klichinsky, Michael, Shestova, Olga, Patel, Prachi R., Kulikovskaya, Irina, Nazimuddin, Farzana, Bhoj, Vijay G., Orlando, Elena J., Fry, Terry J., Bitter, Hans, Maude, Shannon L., Levine, Bruce L., Nobles, Christopher L., Bushman, Frederic D., Young, Regina M., Scholler, John, Gill, Saar I., June, Carl H., Grupp, Stephan A., Lacey, Simon F., Melenhorst, J. Joseph·2018·Nature Medicine

DOI 10.1038/s41591-018-0201-9PMC PMC6511988

Open this paper in CoChat — free account

Abstract

We report a patient relapsing 9 months after CD19-targeted CAR T cell (CTL019) infusion with CD19- leukemia that aberrantly expressed the anti-CD19 CAR. The CAR gene was unintentionally introduced into a single leukemic B cell during T cell manufacturing, and its product bound in cis to the CD19 epitope on the surface of leukemic cells, masking it from recognition by and conferring resistance to CTL019.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41591-018-0201-9

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Self-citation
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Self-citation
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citation
Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor
Söker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998) · Cell · doi:10.1016/s0092-8674(00)81402-6 · Cited by 2,493
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Self-citation
Chimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,411
Self-citation

Show all 36 references

Research works printed but not linked: 1

Salvatore, G., Beers, R., Margulies, I., Kreitman, R. J. & Pastan, I. Clin. Cancer Res. 8, 995–1002 (2002).

Sorted by citations

Items 401–500 of 659

Establishing a GMP-compliant manufacturing process and phase-appropriate analytics for early development of a FiCAR T-cell product with a novel CAR spacer
Luostarinen, A., Vuorela, A., Kerkelä, E., Patrikoski, M., Kotovuori, A., Koski, J., Ahoniemi, J., Lähteenmäki, K., Lehtisalo, J., Oja, T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-92736-9 · Cited by 8
Harnessing the potential of gene-editing technology to overcome the current bottlenecks of CAR-T cell therapy in T-cell malignancies
Ismail, A., Khormi, M. A., Mawkili, W., Albaqami, A., Areshi, S. M., Aborasain, A. M., Hegazy, M. M., Amin, A. H., & Abo-Zaid, M. A. (2025) · Experimental Hematology · doi:10.1016/j.exphem.2025.104762 · Cited by 9
Monocyte-adhesive peptidyl liposomes for harnessing monocyte homing to tumor tissues
Chang, C., Huang, S.-H., Chen, C., Jian, C., Chang, C.-C., Chang, Y.-Y., Jung, M., Lee, H., & Cheng, B. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113672 · Cited by 8
Emerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment
Wang, R., Duan, X., Li, J., Zhang, C., & Shen, L. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-4308 · Cited by 10
Mechanisms underlying resistance to CAR-T cell therapy and strategies for enhancement
Wu, A., Zhang, T., Yu, H., Cao, Y., Zhang, R., Shao, R., Liu, B., Chen, L., Xu, K., Chen, W., et al. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.04.002 · Cited by 9
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
Sullivan, R. J., Cillo, A. R., Ferris, R. L., Jenkins, R. W., Kluger, H. M., Kok, M., Lipson, E. J., Paruzzo, L., Redmond, W. L., Ruella, M., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011929 · Cited by 11
Self-citation
Advancing CAR-T cell therapy: Insights into patient biology, leukapheresis, and cryopreservation
Blanco, B., Mfarrej, B. G., LU, H., Irwin, L., Salmon, J., Morris, D., & Bowden, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.045 · Cited by 9
Advances in CAR design
Heard, A. D., Chang, J., Warrington, J. M., & Singh, N. (2021) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2021.101304 · Cited by 8
Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?
Miyao, K., Yokota, H., & Sakemura, R. L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1082235 · Cited by 8
Emodin is a Potential Drug Targeting CD44-positive Hepatocellular Cancer
Gao, Y., Li, Y., Zhu, Y., Luo, Q., YiFeng, L., Wen, K., Du, B., Xi, X., & Li, G. (2023) · Current Cancer Drug Targets · doi:10.2174/0115680096256913231101103719 · Cited by 8
A novel mitochondrial pyruvate carrier inhibitor drives stem cell-like memory CAR T cell generation and enhances antitumor efficacy
Wenes, M., Lepez, A., Arinkin, V., Maundrell, K., Barábas, O., Simonetta, F., Dutoit, V., Romero, P. J., Martinou, J., & Migliorini, D. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200897 · Cited by 10
Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies
Schwab, R. D., Bedoya, D. M., King-Peoples, T. R., Levine, B. L., & Posey, A. D. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0146-4_15 · Cited by 9
Self-citation
Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells
Wallace, D. S., & Reagan, P. M. (2021) · Drugs · doi:10.1007/s40265-021-01497-y · Cited by 8
Exploring standards for multicellular mammalian synthetic biology
Glykofrydis, F., & Elfick, A. P. D. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.06.001 · Cited by 8
T-cell Acute Lymphoblastic Leukemia
Usman, S. J., & O’Dwyer, K. M. (2024) · Advances in Oncology · doi:10.1016/j.yao.2024.02.007 · Cited by 8
CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies
Mi, J., Xu, J., Zhou, J., Zhao, W., Zhu, C. H., Melenhorst, J. J., & Chen, S. (2021) · Frontiers of Medicine · doi:10.1007/s11684-021-0904-z · Cited by 8
Self-citation
Efficacy and risk of donor-derived CAR-T treatment of relapsed B-cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation
Deng, L., Yu, X., Song, X., Guan, R., Li, W., Hou, Y., Shao, Y., Zhao, Y., Wang, J., Liu, Y., et al. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.05.021 · Cited by 7
Smart Cell Therapy: an industry perspective on macrophages as living drugs
Rodgers, D. T., Novobrantseva, T. I., & Bárcia, R. N. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.12.002 · Cited by 7
Cell adhesion molecule ITGB2 promotes CAR-T cell therapy in B-cell malignancies
Su, Y., Xu, X., Yang, G., Chen, B., Chen, X., Chen, Q., Lv, K., Zhang, Z., Liu, H., Qi, X., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218014 · Cited by 7
Nanobody CAR-T cells in cancer: From molecular design to clinical translation
Eisa, A. R., Razavi, F. T., Hoseinzadeh, A., Haghmorad, D., & Baharlou, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118819 · Cited by 7
Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy
Cianga, V., Antohe, I., Minciună, C., & Dascalescu, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1738558 · Cited by 8
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukemia in children and young adults
Feuchtinger, T. F., Bader, P., Subklewe, M., Breidenbach, M., Willier, S. M., Metzler, M., Gökbuget, N., Hauer, J., Müller, F., Schlegel, P., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.283780 · Cited by 8
Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma
Ren, T., & Huang, Y. B. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03443-7 · Cited by 8
Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report
Schultz, L. M., Patel, S., Davis, K. L., Ramakrishna, S., Sahaf, B., Bhatia, N., Baggott, C., Erickson, C., Majzner, R. G., Oak, J. S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001073 · Cited by 7
Strategies to overcome the side effects of chimeric antigen receptor T cell therapy
Godarzee, M. M., Hussen, B. M., Razmara, E., Hakak‐Zargar, B., Mohajerani, F., Dabiri, H., Rasul, M. F., Ghazimoradi, M. H., Babashah, S., & Sadeghizadeh, M. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14724 · Cited by 7
Overcoming resistance to anti‐CD19 CAR T‐cell therapy in B‐cell malignancies
Yang, X., Wei, J., & Zhou, J. (2022) · Hematological Oncology · doi:10.1002/hon.3036 · Cited by 7
Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies
Liao, Y., Hsu, S., & Chiou, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042416 · Cited by 7
Delivery of gene therapy to resting immune cells for an HIV cure
Ahlenstiel, C., & Turville, S. G. (2019) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000531 · Cited by 7
State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment
Esmaeilzadeh, A., Hadiloo, K., Yaghoubi, S., Makoui, M. H., & Mostanadi, P. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01056-7 · Cited by 7
A clonally expanded nodal T-cell population diagnosed as T-cell lymphoma after CAR-T therapy
Maurer, K., Weir, J. A., Nagler, A., Haradhvala, N., Bharadwaj, H., Shapiro, J., Alakwe, S., Kumar, V., Waller, B. F., McDonough, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62709-7 · Cited by 4
Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy
Sioud, M., & Casey, N. P. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020909 · Cited by 9
Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function
Dietze, K. A., Nguyen, K., Pathni, A., Fazekas, F., Sun, W., Rosati, E., Baker, J. M., Figueroa, M. G., Gebru, E., Yamoah, D., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02654-z · Cited by 7
Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL
Lussana, F., Cavallaro, G., Simone, P. D., & Rambaldi, A. (2023) · Cancers · doi:10.3390/cancers15041349 · Cited by 7
Advancing the frontiers of adaptive cell therapy: A transformative mechanistic journey from preclinical to clinical settings
Mannan, A., Kakkar, C., Dhiman, S., & Singh, T. G. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111095 · Cited by 6
Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma
Zhang, X., Xu, K., Gale, R. P., & Pan, B. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02463-4 · Cited by 6
Turning “trashed” genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells
Wang, Y., Jiang, J., Shang, K., Xu, X., & Sun, J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.02.028 · Cited by 6
CD19 -targeted CAR T therapy treating hematologic malignancies: hidden danger is the next neighbor to security?
Ye, X.-S., Ge, M., Tan, M., Wu, Y.-Q., Zhang, H.-Q., & Fu, Z.-X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1490491 · Cited by 8
Role of CAR-T cell therapy in B-cell acute lymphoblastic leukemia
Greinix, H. (2019) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-019-00541-8 · Cited by 6
Cancer immunotherapy with CAR T cells: well-trodden paths and journey along lesser-known routes
Smole, A. (2022) · Radiology and Oncology · doi:10.2478/raon-2022-0049 · Cited by 8
CRISPR-based precision medicine for hematologic disorders: Advancements, challenges, and prospects
Sahu, S., Poplawska, M., Lim, S. H., & Dutta, D. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122165 · Cited by 9
A biomaterial platform for T cell-specific gene delivery
Pandit, S., Smith, B. E., Birnbaum, M. E., & Brudno, Y. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.02.013 · Cited by 6
Enrichment of T-lymphocytes from leukemic blood using inertial microfluidics toward improved chimeric antigen receptor-T cell manufacturing
Elsemary, M. T., Maritz, M. F., Smith, L. E., Warkiani, M. E., & Thierry, B. (2024) · Cytotherapy · doi:10.1016/j.jcyt.2024.05.005 · Cited by 6
Synthetic Biology Approaches in Immunology
Mohammad, N. B., Lam, C. C. K., & Truong, K. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b01081 · Cited by 6
Hematopathologic Correlates of CAR T-Cell Therapy
Dolan, J. G., Paessler, M. E., Rheingold, S. R., & Pillai, V. (2021) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2021.03.012 · Cited by 6
Chimäre Antigenrezeptoren (CARs) in der Onkologie: eine Übersicht zu klinischer Anwendung und neuen Entwicklungen
Michels, A., Hartmann, J., & Buchholz, C. J. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03222-8 · Cited by 7
Influence of CAR T-cell therapy associated complications
Umair, M., Lai, X., Xue, Y.-B., & Yao, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1494986 · Cited by 6
Facts and Hopes: CAR T-Cell Therapy and Immune Contexture in Non-Hodgkin Lymphoma
Hijazi, A., Locke, F. L., Scholler, N., Mattie, M., Filosto, S., Bedognetti, D., & Galon, J. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2267 · Cited by 6
A differentiated and durable allogeneic strategy applicable to cell therapies
Jetley, U., Balwani, I., Sharma, P., Miller, I. C., Luther, A., Dutta, I., Saravanan, N., Goel, S., Zhang, Q., Zhang, B., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.10.001 · Cited by 6
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells
Talleur, A. C., Naik, S., & Gottschalk, S. M. (2023) · Hematology · doi:10.1182/hematology.2023000424 · Cited by 5
CAR T-cells for acute leukemias in children: current status, challenges, and future directions
Dourthe, M.-É., & Baruchel, A. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10261-7 · Cited by 5
Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor
Zhang, B., Napoleon, J. V., Liu, X., Luo, Q., Srinivasarao, M., & Low, P. S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000756 · Cited by 5
Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies
Braun, T., & Schrader, A. (2023) · Cancers · doi:10.3390/cancers15092532 · Cited by 5
LncRNA H19 Participates in Leukemia Inhibitory Factor Mediated Stemness Promotion in Colorectal Cancer Cells
Zhu, M., Yu, R., Liu, Y., Geng, X., Liu, Q., Liu, S., Zhu, Y., Li, G., Guo, Y., Xi, X., et al. (2024) · Biochemical Genetics · doi:10.1007/s10528-023-10627-y · Cited by 4
Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma
Goyal, A., & Foss, F. M. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2305356 · Cited by 5
Antibody-targeted T cells and natural killer cells for cancer immunotherapy
Sutherland, A. R., Parlekar, B., Livingstone, D. W., Medina, A. X., Bernhard, W., García, T. H., DeCoteau, J. F., & Geyer, C. R. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02898-3 · Cited by 5
Investigating the response of paediatric leukaemia‐propagating cells to BCL‐2 inhibitors
Diamanti, P., Ede, B. C., Dace, P., Barendt, W. J., Cox, C. V., Hancock, J. P., Moppett, J. P., & Blair, A. (2020) · British Journal of Haematology · doi:10.1111/bjh.16773 · Cited by 5
The challenge to further improvements in survival of patients with T-ALL: Current treatments and new insights from disease pathogenesis
O’Dwyer, K. M. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.11.004 · Cited by 5
Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19+ Tumors
Grover, N. S., Tschernia, N. P., Dotti, G., & Savoldo, B. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01738 · Cited by 5
COL14A1 promotes self-renewal of human liver cancer stem cells through activation of ERK signaling
Kong, R., Liu, H., Shi, Y., Man, Q., & Liu, S. (2021) · Journal of Bio-X Research · doi:10.1097/jbr.0000000000000087 · Cited by 5
Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas
Appelbaum, J., Pinto, N. R., & Orentas, R. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-66181-2.00011-1 · Cited by 5
Lipid-Mediated Insertion of Toll-Like Receptor (TLR) Ligands for Facile Immune Cell Engineering
Zhang, M. H., Slaby, E. M., Stephanie, G., Yu, C., Watts, D. M., Liu, H., & Szeto, G. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00560 · Cited by 4
Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cellsPreprint
Kath, J., Franke, C., Drosdek, V., Du, W., Glaser, V., Fuster‐García, C., Stein, M., Zittel, T., Schulenberg, S., Porter, C. E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.10.565518 · Cited by 5
A novel pseudotype derived of the canine distemper virus for adapter-mediated lentiviral transduction in vivo
Winter, N., Kolbe, C., Ferdos, S., Steiner, L., Bartelsen, N., Lock, D., Engert, F., Engels, B., Assenmacher, M., Schindler, M., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101526 · Cited by 4
Clinical potential of CAR T cell-derived extracellular vesicles (CAR-EVs) in cancer therapy: a cell-free approach
Kale, V. P., & Ingavle, G. C. (2025) · Therapeutic Delivery · doi:10.1080/20415990.2025.2569298 · Cited by 4
CAR-T cell therapy: A therapeutic strategy for cancer treatment
Sharif, S., Sharma, U., & Yadav, A. K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152430 · Cited by 4
TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength
Spiga, M., Potenza, A., Magnani, Z. I., Beretta, S., Camisa, B., Conte, L., Airaghi, A., Mohammadi, N., Perani, L., Doglioni, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-67263-w · Cited by 4
Finding Your CAR
Chen, P., Raghunandan, R., Morrow, J. S., & Katz, S. G. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.04.002 · Cited by 5
SOHO State of the Art Updates and Next Questions | CAR T Cells in T Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Shmidt, D. I., & Mamonkin, M. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.05.018 · Cited by 4
In vivo engineering chimeric antigen receptor immune cells with emerging nanotechnologies
Ren, H., Jin, Y., Huang, H., Wu, W., Dai, X., Fang, W. J., Qin, J., Li, H., & Zhao, P. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102517 · Cited by 4
Improved production and quality of lentiviral vectors by major-splice-donor mutation and co-expression of a novel U1 snRNA-based enhancer
Wright, J., Alberts, B., Hood, A. J. M., Nogueira, C., Miskolczi, Z., Vieira, C. R., Chipchase, D., Lamont, C. M., Goodyear, O. C., Moyce, L. J., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e43732 · Cited by 4
Developing patient-centric specifications for autologous chimeric antigen receptor T cell therapies
Zhang, T., Larson, R. P., Dave, K., Polson, N., & Zhang, H. (2021) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2021.100328 · Cited by 4
Efficient Chimeric Antigen Receptor T-Cell Generation Starting with Leukoreduction System Chambers of Thrombocyte Apheresis Sets
Xhaxho, S., Chen-Wichmann, L., Kreissig, S., Windisch, R., Gottschlich, A., Nandi, S., Schabernack, S., Kohler, I., Kellner, C., Kobold, S., et al. (2023) · Transfusion Medicine and Hemotherapy · doi:10.1159/000532130 · Cited by 4
New approaches of chimeric antigen receptor (CAR)-immune cell-based therapy in gastric cancer; highlight CAR-T and CAR-NK
Jasim, S. A., Pallathadka, H., Sivaprasad, G. V., Kumar, A., Mustafa, Y. F., Mohammed, J. S., Eldesoqui, M. B., Pramanik, A., Abdukarimovna, R. K., & Zwamel, A. H. (2025) · Functional & Integrative Genomics · doi:10.1007/s10142-025-01584-3 · Cited by 4
The road ahead for chimeric antigen receptor T cells
Stewart, C. M., Siegler, E. L., & Kenderian, S. S. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf047 · Cited by 4
Novel and effective tandem CD38 and CD19 targeting CAR-T cells inhibit hematological tumor immune escape
Liu, X., Feng, Y., Song, Z., Liu, J., Luo, Z., Yu, G., & Wang, J. (2025) · Cellular Immunology · doi:10.1016/j.cellimm.2025.104950 · Cited by 4
A new sort of cells for chimeric antigen receptor T-cell therapies—isolating CD14–CD127+ T cells for chimeric antigen receptor T-cell manufacture
Luo, Y., Qie, Y., Gadd, M. E., Hundal, T., Brim, A. D., Vazquez-Rosario, I. K., & Qin, H. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.04.068 · Cited by 4
Efficient Editing of an Adenoviral Vector Genome with CRISPR/Cas9
Li, Q., Wang, H., Gong, C.-Y., Zhao, C., Yang, J.-X., Shao, H., & Zhang, W. (2020) · Indian Journal of Microbiology · doi:10.1007/s12088-020-00905-3 · Cited by 4
Role of Nanomedicine for Cancer Immunotherapy
Nasra, S., Chaudhari, R. H., & Kumar, A. (2021) · Springer eBooks · doi:10.1007/978-981-15-7564-8_6 · Cited by 4
Protein engineering: a driving force toward synthetic immunology
Cox, J. R., & Blazeck, J. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.09.005 · Cited by 5
Genome-Edited T Cell Therapies
Ottaviano, G., & Qasim, W. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.03.006 · Cited by 4
A non-genetic engineering platform for rapidly generating and expanding cancer-specific armed T cells
Chen, Y.-J., Chen, M. J., Cheng, T., Tsai, Y.-S., Wang, C.-H., Chen, C.-Y., Wu, T.-Y., Tzou, S.-C., Wang, K., Cheng, J., et al. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00929-z · Cited by 4
Cancer Immunotherapy Via Stem Cell-Derived NK Cells
Hosseini, F. S., Ahmadvand, M., Karimi, R., Mousavi, S. A., Ai, J., & Nikbakht, M. (2023) · Immunotherapy · doi:10.2217/imt-2022-0224 · Cited by 4
[Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation].
Ai, H., Yin, Q., Wang, Q., Fu, Y., Wei, X., & Song, Y. (2020) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2020.03.010 · Cited by 4
Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults
Kimble, E. L., & Cassaday, R. D. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1964022 · Cited by 4
Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies
Bourcier, J., & Abdel-Wahab, O. I. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0200 · Cited by 4
Overcoming Resistance and Relapse in CAR-T and CAR-NK Cell Therapies: From Bench to Bedside
Wang, Y., Shao, W., Mao, J., & Ye, Q. (2025) · Research · doi:10.34133/research.1068 · Cited by 5
The race between 4-1BB- and CD28-based CD19 CAR-T products in the therapy of B-cell malignancies
Krawczyk, M., Drużyńska, M., Bednarska, E., & Winiarska, M. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189519 · Cited by 4
From CAR-T Cells to Exosome-Based Immunotherapy: Exploring the Frontiers of Cell-Free Targeted Cancer Therapeutics
Tîrziu, A., Bojin, F. M., Gavriliuc, O. I., Faur, C. I., & Păunescu, V. (2025) · Cells · doi:10.3390/cells15010070 · Cited by 3
Exosome-mediated crosstalk between immune cells and tumor microenvironment in lung cancer: Implications for immune evasion and therapeutic resistance
Tang, R., Juan, Z., Xing, F., Yi, Z., & Fu, Y. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112452 · Cited by 3
Emerging CRISPR Approaches for Countering Immune Evasion: Insight from Recent Studies
Abubakar, S., Abdulsalam, L., Fatty, L., Kanwal, R., Naeem, M., & Ahmad, I. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072930 · Cited by 3
Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases
Li, H., Li, J., Liu, X. D., Wei, X., Zeng, X., Wang, Q. Y., Han, Y., Huang, H., & Qian, P. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01805-7 · Cited by 3
Chimeric antigen receptor T cells march into T cell malignancies
Tang, J., & Zhao, X. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05148-5 · Cited by 3
A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies
Wang, D., Wang, L., Liu, S., Tong, J., Zhu, H., Xu, M., Li, X., Xiang, Z., Sun, Q., Wang, H., et al. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.70022 · Cited by 3
Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness
de Oliveira, B. C., Bari, S. M. N., & Melenhorst, J. J. (2025) · Cancers · doi:10.3390/cancers17030383 · Cited by 3
Self-citation
Systematic review of novel target therapies and clinical trials in chordoma
Zeinali, M., Seraj, F. Q. M., Rawson, C., Azab, M. A., & Karsy, M. J. (2025) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2025.109222 · Cited by 3
Regulating innovation in the early development of cell therapies
Exley, A., & McBlane, J. W. (2020) · Immunotherapy Advances · doi:10.1093/immadv/ltaa011 · Cited by 4
Mécanismes de résistance et d’échappement aux cellules CAR-T
Grinda, T., Brouard, J., Tran, D., & Rubio, M. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.09.002 · Cited by 3
Bringing CAR-T to the Clinic
Jain, M. D., Coney, P., & Locke, F. L. (2022) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-87849-8_10 · Cited by 3
Harnessing the immune system in the treatment of cutaneous T cell lymphomas
Fay, C. J., Awh, K. C., LeBoeuf, N. R., & Larocca, C. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1071171 · Cited by 3
A positive take on negative selection for CAR-T manufacturing
Orentas, R. J. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101218 · Cited by 3

Authors: Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., Nazimuddin, F., Bhoj, V. G., Orlando, E. J., Fry, T. J., Bitter, H., Maude, S. L., Levine, B. L., Nobles, C. L., Bushman, F. D., Young, R. M., Scholler, J., Gill, S. I., June, C. H., Grupp, S. A., Lacey, S. F., & Melenhorst, J. J.
Affiliations: Abramson Cancer Center (US)
Children's Hospital of Philadelphia (US)
University of Pennsylvania (US)
Children's Hospital Colorado (US)
Corresponding author: June, Carl H.
Melenhorst, J. Joseph
ORCID: Ruella, Marco
Xu, Jun
Barrett, David M.
Fraietta, Joseph A.
Reich, Tyler J.
Klichinsky, Michael
Patel, Prachi R.
Kulikovskaya, Irina
Bhoj, Vijay G.
Orlando, Elena J.
Fry, Terry J.
Bitter, Hans
Maude, Shannon L.
Levine, Bruce L.
Nobles, Christopher L.
Bushman, Frederic D.
Young, Regina M.
Scholler, John
Gill, Saar I.
June, Carl H.
Grupp, Stephan A.
Lacey, Simon F.
Melenhorst, J. Joseph
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 2018-10
Volume: 24
Issue: 10
Pages: 1499-1503
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/s41591-018-0201-9
PMC: PMC6511988
OpenAlex: W2893691711
Cited by: 659
References: 36
Citations by year: 2026: 61 · 2025: 73 · 2024: 83 · 2023: 84 · 2022: 83 · 2021: 91 · 2020: 91 · 2019: 78 · 2018: 14
FWCI: 25.75
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (K99CA212302, R00CA212302, T32CA009140, R01CA120409, P01CA214278)
Topics: Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords: CAR T-cell therapy, CD19, tisagenlecleucel, B-cell acute lymphoblastic leukemia, CAR T cell manufacturing, relapse
MeSH terms: Receptors, Chimeric Antigen, Adult, Epitopes, B-Lymphocytes, Humans, Leukemia, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Antigens, CD19, Drug Resistance, Neoplasm, Young Adult, Cell- and Tissue-Based Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks